These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 11448727)
41. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Phillips MI Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099 [TBL] [Abstract][Full Text] [Related]
42. Synthetic oligonucleotides: the development of antisense therapeutics. Monteith DK; Levin AA Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666 [TBL] [Abstract][Full Text] [Related]
43. Clinical development of antisense oligonucleotides as anti-cancer therapeutics. Chen HX Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768 [No Abstract] [Full Text] [Related]
44. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680 [TBL] [Abstract][Full Text] [Related]
45. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. White PJ; Anastasopoulos F; Pouton CW; Boyd BJ Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730 [TBL] [Abstract][Full Text] [Related]
46. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739 [TBL] [Abstract][Full Text] [Related]
47. Progress in antisense therapeutics discovery and development. Crooke ST Ciba Found Symp; 1997; 209():158-64; discussion 164-8. PubMed ID: 9383575 [TBL] [Abstract][Full Text] [Related]
48. The potential of antisense as a CNS therapeutic. Godfray J; Estibeiro P Expert Opin Ther Targets; 2003 Jun; 7(3):363-76. PubMed ID: 12783572 [TBL] [Abstract][Full Text] [Related]
53. Genasense: it ain't over till the fat lady sings. Stein CA Oligonucleotides; 2007; 17(4):345-8. PubMed ID: 17949263 [No Abstract] [Full Text] [Related]
54. G3139, a BCL-2 antisense oligo-nucleotide, in AML. Marcucci G; Stock W; Dai G; Klisovic MI; Maharry K; Shen T; Liu S; Sher DA; Lucas D; Zwiebel A; Larson RA; Caligiuri MA; Bloomfield CD; Chan KK; Grever MR; Byrd JC Ann Hematol; 2004; 83 Suppl 1():S93-4. PubMed ID: 15124691 [No Abstract] [Full Text] [Related]
55. Antisense drug discovery and development. Yamamoto T; Nakatani M; Narukawa K; Obika S Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846 [TBL] [Abstract][Full Text] [Related]
56. Preclinical and clinical experience of antisense therapy for solid tumors. Webb MS; Zon G Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760 [TBL] [Abstract][Full Text] [Related]
57. Antisense oligonucleotide treatments for psoriasis. White PJ; Atley LM; Wraight CJ Expert Opin Biol Ther; 2004 Jan; 4(1):75-81. PubMed ID: 14680470 [TBL] [Abstract][Full Text] [Related]
59. [Current status of antisense drugs]. Li XJ Sheng Li Ke Xue Jin Zhan; 2000 Apr; 31(2):115-9. PubMed ID: 12545727 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. Flores-Aguilar M; Besen G; Vuong C; Tatebayashi M; Munguia D; Gangan P; Wiley CA; Freeman WR J Infect Dis; 1997 Jun; 175(6):1308-16. PubMed ID: 9180168 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]